CASP3 and neoplasm: The same concept of using heterobivalent peptidic agents comprising an RGD moiety for tumor therapy driven by caspase-3-induced apoptosis induction was also applied in the case of 43, consisting of c(RGDyD) (cyclo-(Arg-Gly-Asp-DTyr-Asp)) and [Cys3,4,10, DPhe7, Arg11]αMSH3–13, which binds to the MC1R (melanocortin 1 receptor) for melanoma targeting and uptake [106].